Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Significance Statement: Although angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) medications are mainstays of treatment in CKD, the frequency of ACE/ARB use has not been well characterized in this population. Nationally representative data from 1999 to 2014 showed that overall ACE/ARB use during this period was only 34.9% among those with CKD; use rose significantly with time (from 25.5% in 1999–2002 to 40.1% in 2011–2014) but seemed to level off after the early 2000s, a trend similarly observed in multiple CKD subgroups. Overall, regardless of era, ACE/ARB use in CKD was the exception unless concomitant illnesses, like diabetes mellitus or cardiac disease, were present. This suggests that a significant opportunity exists for improvement in the care in community-based CKD. Background: Although hypertension is common in CKD and evidence-based treatment of hypertension has changed considerably, contemporary and nationally representative information about use of angiotensin-converting enzyme (ACEs) inhibitors or angiotensin II receptor blockers (ARBs) in CKD is lacking. Methods: We examined ACE/ARB trends from 1999 to 2014 among 38,885 adult National Health and Nutrition Examination Survey participants with creatinine-based eGFR<60 ml/min per 1.73 m 2 or urinary albumin-to-creatinine ratio ≥30 mg/g. Results: Of 7085 participants with CKD, 34.9% used an ACE/ARB. Across four eras studied, rates of use rose significantly (rates were 25.5% in 1999–2002, 33.3% in 2003–2006, 39.0% in 2007–2010, and 40.1% in 2011–2014) but appeared to plateau after 2003. Among those with CKD, use was significantly greater among non-Hispanic white and black individuals (36.1% and 38.2%, respectively) and lower among Hispanic individuals (26.7%) and other races/ethnicities (29.3%). In age-, sex-, and race/ethnicity-adjusted models, ACE/ARB use was significantly associated with era (adjusted odds ratios [aOR], 1.41; 95% confidence interval [95% CI], 1.14 to 1.74 for 2003–2006, 1.84; 95% CI, 1.48 to 2.28 for 2007–2010, and 2.02; 95% CI, 1.61 to 2.53 for 2011–2014 versus 1999–2002); it also was significantly associated with non-Hispanic black versus non-Hispanic white race/ethnicity (aOR, 1.40; 95% CI, 1.19 to 1.66). Other multivariate associations included older age, men, elevated BMI, diabetes mellitus, treated hypertension, cardiac failure, myocardial infarction, health insurance, and receiving medical care within the prior year. Conclusions: Rates of ACE/ARB use increased in the early 2000s among United States adults with CKD, but for unclear reasons, use appeared to plateau in the ensuing decade. Research examining barriers to care and other factors is needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 20 years ago, similar expectations were held for ACE inhibitors and ARBs, but implementation of this standard of care for diabetes and CKD is strikingly low, in the range of 20% to 40%, even in contemporary reports from communities and health care systems (96,97).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [96]
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358
“However, implementation gaps have been observed even for lower-cost therapies for cardiovascular and kidney disease, 34 and some of these therapies are now available (or soon to be available) in generic formulations.”
BackgroundTuttle, K. R., Alicic, R. Z., Duru, O. K., Jones, C. R., Daratha, K. B., Nicholas, S. B., McPherson, S. M., Neumiller, J. J., Bell, D. S., Mangione, C. M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18169 · Cited by 275
Palaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease
Chu, C. D., Xia, F., Du, Y., Singh, R., Tuot, D. S., Lamprea-Montealegre, J. A., Gualtieri, R., Liao, N., Kong, S. X., Williamson, T. E., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.26230 · Cited by 163
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 146
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
“Nearly 20 years ago, similar expectations were held for ACE inhibitors and ARBs, but implementation of this standard of care for diabetes and CKD is strikingly low, in the range of 20% to 40%, even in contemporary reports from communities and health care systems (96,97).”
BackgroundNeuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., Cannon, C. P., Charytan, D. M., Edwards, R., Górriz, J. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab497 · Cited by 123
“Inhibition of the RAAS system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is the standard of care for people with T2DM and CKD, but these agents are known to increase the risk of hyperkalaemia,(6) contributing at least partly to non-prescription or discontinuation of the…”
BackgroundCumulative Incidence of Mortality Associated with Cardiovascular–Kidney–Metabolic (CKM) Syndrome
Claudel, S. E., Schmidt, I. M., Waikar, S. S., & Verma, A. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000637 · Cited by 120
Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02980322 · Cited by 87
Trends in Chronic Kidney Disease Care in the US by Race and Ethnicity, 2012-2019
Chu, C. D., Powe, N. R., McCulloch, C. E., Crews, D. C., Han, Y., Bragg‐Gresham, J. L., Saran, R., Koyama, A. K., Burrows, N. R., Tuot, D. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.27014 · Cited by 85
Eckardt, K., Delgado, C., Heerspink, H. J. L., Pecoits‐Filho, R., Ricardo, A. C., Stengel, B., Tonelli, M. A., Cheung, M., Jadoul, M. Y., Winkelmayer, W. C., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.013 · Cited by 104
“110,111 115 As the number of disease-modifying medications increases, questions arise about the optimal use of combination therapies in individual patients, based on diagnosis and risk of progression.”
BackgroundOvercoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Nee, R. J., Yuan, C. M., Narva, A. S., Yan, G., & Norris, K. C. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac283 · Cited by 97
Nicholas, S. B., Daratha, K. B., Alicic, R. Z., Jones, C. R., Kornowske, L. M., Neumiller, J. J., Fatoba, S., Kong, S. X., Singh, R., Norris, K. C., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15194 · Cited by 91
“To address the limitations inherent in EHR data, we defined diabetes by laboratory tests of haemoglobin A1c and blood glucose, prescriptions for glucose-lowering agents, and administrative codes.(23,24) We could not specifically classify diabetes as type 1 or type 2 or by duration because of the limitations of misclas…”
MethodRenin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease
Walther, C. P., Winkelmayer, W. C., Richardson, P., Virani, S. S., & Navaneethan, S. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa300 · Cited by 61
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 62
Alkhatib, L., Díaz, L. A. V., Varma, S., Chowdhary, A., Bapat, P., Pan, H., Kukreja, G., Palabindela, P., Selvam, S. A., & Kalra, K. (2023) · Cureus · doi:10.7759/cureus.34572 · Cited by 56
“1: [50], 2: [51], 3: [52], 4: [53], 5: [54], 6: [55], 7: [56], and 8: [57]”
Chu, C. D., Powe, N. R., McCulloch, C. E., Banerjee, T., Crews, D. C., Saran, R., Bragg‐Gresham, J. L., Morgenstern, H., Pavkov, M. E., Saydah, S., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16281 · Cited by 41
Neuen, B. L., Bello, A. K., Levin, A., Lunney, M., Osman, M. A., Ye, F., Ashuntantang, G., Bellorín-Font, E., Gharbi, M. B., Davison, S. N., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001467 · Cited by 51
Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000248 · Cited by 40
“6 Data indicate similar trends in low-and middle-income countries.”
BackgroundKelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 45
“Indeed, underuse [58] and underdosage [59] of ACEis and ARBs has been reported.”
BackgroundChronic kidney disease detection, staging and treatment in cardiovascular disease prevention
Lamprea-Montealegre, J. A., Shlipak, M. G., & Estrella, M. M. (2021) · Heart · doi:10.1136/heartjnl-2020-318004 · Cited by 36
Loutradis, C., Price, A. M., Ferro, C. J., & Sarafidis, P. A. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00504-9 · Cited by 34
“Despite evidence and recommendations, RAS blockers are typically underprescribed and easily stopped in patients with CKD, indicating the lack of confidence of physicians on the possible benefits of treatment [70, 71].”
BackgroundRenin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?
Burnier, M. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.002 · Cited by 39
“Interestingly, this percentage is lower than recent figures reported by Murphy et al.(20) Among 7,085 adults with CKD participating in theNationalHealth andNutrition Examination Survey in 2011 to 2014, a total of 40.”
ResultInfluentialBarriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study
McCoy, I. E., Han, J., Montez‐Rath, M. E., & Chertow, G. M. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.038 · Cited by 32
Borrelli, S., Nicola, L. D., Minutolo, R., Conte, G., Chiodini, P., Cupisti, A., Santoro, D., Calabrese, V., Giannese, D., Garofalo, C., et al. (2021) · Nutrients · doi:10.3390/nu13030942 · Cited by 33
“Furthermore, more than 75% patients received RAASI therapy (Figure 1); this is at variance with the observed lower-than-expected use of these agents in an unselected CKD population where only 40% of the patients were treated [28].”
Neuen, B. L., Jun, M., Wick, J., Kotwal, S. S., Badve, S. V., Jardine, M., Gallagher, M., Chalmers, J. P., Nallaiah, K., Perkovic, V., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100988 · Cited by 34
“1 4 Despite clear evidence from multiple large, randomised trials that SGLT2 inhibitors reduce the risk of kidney failure or death in people with CKD, the uptake of these agents in routine practice remains low.”
BackgroundInfluentialTransforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 29
“25 years and extensive clinical experience with RAS blockers, recent studies have shown that 25%–40% of patients with CKD, with or without diabetes, who should be given these drugs are receiving them (9,10).”
BackgroundArora, N., Katz, R., & Bansal, N. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2019.12.007 · Cited by 30
“Although data regarding patients with advanced CKD are sparse, it has been suggested that there is an increasing prevalence of prescriptions for RAS inhibitors among this population,(19,22) although use appears to have reached a plateau in the past decade.(23)”
BackgroundNeuen, B. L., Jardine, M., & Perkovic, V. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz252 · Cited by 28
“Current data suggest that a substantial proportion of patients with CKD who would benefit from treatment with RAS blockade still do not receive it [48].”
BackgroundRocheleau, G. L. Y., Lee, T., Mohammed, Y., Goodlett, D. R., Burns, K. D., Cheng, M. P., Tran, K. C., Sweet, D. D., Marshall, J. C., Slutsky, A. S., et al. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005589 · Cited by 38
“ARBs and ACE inhibitors are commonly used in hypertension (59%) (15), chronic kidney disease (CKD) (16), and diabetes (32%) (17).”
BackgroundInfluentialLee, T., Cau, A., Cheng, M. P., Levin, A., Lee, T. C., Vinh, D. C., Lamontagne, F., Singer, J., Walley, K. R., Murthy, S., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.03.001 · Cited by 23
Mottl, A. K., & Nicholas, S. B. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.003 · Cited by 33
Rikin, S., Deccy, S., Zhang, C., Crandall, J. P., Deng, Y., & Golestaneh, L. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07863-0 · Cited by 22
“In this predominantly Black and Hispanic community, we also found racial and ethnic disparities in prescriptions for SGLT2i, but not for RAASi, suggesting that systemic racism may exacerbate barriers to implementing novel evidence-based medications for patients of color.24 This study is the first to concurrently evalu…”
BackgroundMethodResultInfluentialMorton, J. I., McDonald, S. P., Salim, A., Liew, D., Shaw, J. E., & Magliano, D. J. (2021) · Diabetes Care · doi:10.2337/dc21-0220 · Cited by 21
SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review
Maxson, R., Starr, J. A., Sewell, J., & Lyas, C. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.10.014 · Cited by 27
Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021
Rossing, P., & Epstein, M. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.11.019 · Cited by 20
Equity and Quality of Global Chronic Kidney Disease Care: What Are We Waiting for?
Luyckx, V. A., Elmaghrabi, A., Sahay, M., Scholes-Robertson, N. J., Solá, L., Speare, T., Tannor, E. K., Tuttle, K. R., & Okpechi, I. G. (2023) · American Journal of Nephrology · doi:10.1159/000535864 · Cited by 25
“In various studies, despite clear indications and over 15 years since approval for use in diabetes and CKD, the use of these agents remained at around 20 – 40% based on review of US real-world health records [22, 23].”
BackgroundShibata, R., Taguchi, K., Kaida, Y., & Fukami, K. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02277-y · Cited by 23
“Renin–angiotensin system (RAS) inhibitors and/or immunosuppressant therapies have been commonly used to prevent progression of kidney injury in CKD patients [4].”
BackgroundBarriers to Care: New Medications and CKD
Kim, D., Perkovic, V., & Kotwal, S. S. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.012 · Cited by 17
“Despite being a foundation of CKD management and strongly recommended in clinical guidelines based on high quality evidence, renin-angiotensin system blockers remain underutilized, 5,6 with similar trends observed for SGLT2 inhibitor and GLP-1 RA therapy in diabetes.”
BackgroundRetaining Race in Chronic Kidney Disease Diagnosis and Treatment
Williams, P. T. (2023) · Cureus · doi:10.7759/cureus.45054 · Cited by 20
“The NHANES study also showed 40% greater odds for ACEi and ARB use in Blacks than Whites [213].”
BackgroundSodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
Li, J., Fagbote, C. O., Zhuo, M., Hawley, C. E., & Paik, J. M. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz100 · Cited by 15
“The trend of ACEi/ARB usage rates in patients with diabetes and CKD has decreased since the early 2000s [28, 29], possibly due to resultant hyperkalemia.”
Nephrologist Performance in the Merit-Based Incentive Payment System
Tummalapalli, S. L., Mendu, M. L., Struthers, S. A., White, D. L., Bieber, S. D., Weiner, D. E., & Ibrahim, S. A. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.06.006 · Cited by 13
Edwards, N. C., Ferro, C. J., & Townend, J. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad194 · Cited by 14
Miyamoto, S., Heerspink, H. J. L., de Zeeuw, D., Sakamoto, K., Yoshida, M., Toyoda, M., Suzuki, D., Hatanaka, T., Nakamura, T., Kamei, S., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.019 · Cited by 18
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Nicola, L. D., Cozzolino, M. G., Genovesi, S., Gesualdo, L., Grandaliano, G., & Pontremoli, R. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01336-7 · Cited by 17
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
Vasco, M. A. E., Fantaye, S. H., Raghunathan, S., & Solis‐Herrera, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15773 · Cited by 13
“26 Although some benefit has been shown with these drugs, and they are included in treatment guidelines for diabetes and CKD, not all may be suitable for patients with T1D and CKD.”
InfluentialNeumiller, J. J., Shubrook, J. H., Manley, T., Alicic, R. Z., & Tuttle, K. R. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab271 · Cited by 11
National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 16
Russell, J. A., Marshall, J. C., Slutsky, A. S., Murthy, S., Sweet, D., Lee, T., Singer, J., Patrick, D. M., Du, B., Peng, Z., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040768 · Cited by 11
Chu, C. D., Powe, N. R., Estrella, M. M., Shlipak, M. G., McCoy, I. E., & Tuot, D. S. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.07.010 · Cited by 11
Jacobs, J. A., Zheutlin, A. R., Derington, C. G., King, J. B., Pandey, A., & Bress, A. P. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100624 · Cited by 10
“In a 1999 – 2014 NHANES analysis, prevalent use of ACEI or ARB was only 35 % [14].”
Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes
Ku, E., McCulloch, C. E., Copeland, T. P., Inker, L. A., Tighiouart, H., & Sarnak, M. J. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.03.013 · Cited by 8
Weldon, S. M., Cogan, D. A., Cerny, M. A., Frederick, K. S., Gueneva-Boucheva, K., Clifford, H. E., Kugler, S. Z., Marshall, D. R., Richman, J. G., & Brown, N. F. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103649 · Cited by 9
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 9
Yi, T. W., Atiquzzaman, M., Zheng, Y., Smyth, B. J., Jardine, M., & Levin, A. (2022) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221145068 · Cited by 7
Rikin, S., Bauman, L. J., Arnaoudova, I., Palo, K. E. D., Suda, N., Gupta, S., Deng, Y., & Golestaneh, L. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004155 · Cited by 8
Chu, C. D., Dohan, D. P., Estrella, M. M., Shlipak, M. G., & Tuot, D. S. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02454-w · Cited by 5
Bhandari, S., & Chadburn, M. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.09.014 · Cited by 6
Early eGFR decline after SGLT2i initiation: knowns and unknowns
Gregg, L. P., & Navaneethan, S. D. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.021 · Cited by 8
Tummalapalli, S. L., Struthers, S. A., White, D. L., Beckrich, A. L., Brahmbhatt, Y. G., Erickson, K. F., Garimella, P. S., Gould, E. R., Gupta, N., Lentine, K. L., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000163 · Cited by 5
Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial
Tran, K. C., Asfar, P., Cheng, M. P., Demiselle, J., Singer, J., Lee, T., Sweet, D. D., Boyd, J., Walley, K. R., Haljan, G., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae306 · Cited by 5
“…it was 0.79. the meta-analysis [21] suggest some caution for use of ARBs in hospitalized patients in whom ARBs are commonly prescribed (eg, hypertension, 59% patients receive ARBs [28]; hypertensive patients with chronic kidney disease, 35% [29]; diabetics, 32% [30]; and heart failure, 52% [31]).”
BackgroundInfluentialAge- and Race-Specific Changes in ESKD Incidence over Four Decades
Fwu, C., Eggers, P. W., Norton, J. M., Gipson, D. S., Kimmel, P. L., Schulman, I. H., Chan, K. E., Bennett, K. K., & Mendley, S. R. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000310 · Cited by 5
“34,35 We can only speculate whether these gaps were even wider in prior decades and the decrease in incidence of ESKD in some patient groups (and even the slowing of ESKD growth in White adults) is because of modest improvements in screening and treatment of CKD. Disparities in access to care and…”
BackgroundPark, K. J., Unitan, R., & Thorp, M. L. (2020) · The Permanente Journal · doi:10.7812/tpp/20.210 · Cited by 7
Sandhu, A. T., Kohsaka, S., Lin, S., Woo, C. Y., Goldstein, M. K., & Heidenreich, P. A. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.06.004 · Cited by 4
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
Heart Failure and Chronic Kidney Disease Patients
Rossignol, P., & Pitt, B. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.027 · Cited by 4
Nicholas, S. B., Alicic, R. Z., & Shen, J. I. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100590 · Cited by 4
“Unfortunately, despite consensus from KDIGO, the ADA, and the AHA, use of these agents remains consistently and unacceptably low.(15-18) Notably, among 1,375 participants in the National Health and Nutrition Examination Survey (2017-2020) with type 2 diabetes and eGFR >30 mL/min/1.”
BackgroundChakrabarti, A. K., Drexler, Y. R., Swift, S. L., Lash, J. P., Kaplan, R. C., Perreira, K. M., Mendoza, J. M., Daviglus, M. L., Pirzada, A., Sotres‐Alvarez, D., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000656 · Cited by 4
“41 Another limitation is that we are unable to adjust for the use of antiproteinuric medication, including renin-angiotensin system inhibitors, since these are antihypertensive medications and therefore included in the LE8 BP component score.”
Garofalo, C., Borrelli, S., Stefano, T. D., Nicola, L. D., Vita, C., Peruzzu, N., Netti, A., Conte, G., Provenzano, M., & Minutolo, R. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02944-1 · Cited by 3
Ohkuma, T., Harris, K., Cooper, M. E., Grobbee, D. E., Hamet, P., Harrap, S. B., Mancia, G., Marre, M., Patel, A. A., Rodgers, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00180122 · Cited by 4
“Underprescription of RAS inhibitors has been reported, especially among high-risk patients with CKD, cardiovascular disease, and heart failure who would be expected to obtain significant benefits from RAS inhibition (9,11,12).”
BackgroundMorton, J. I., McDonald, S. P., Salim, A., Liew, D., Shaw, J. E., & Magliano, D. J. (2021) · doi:10.2337/figshare.14363783 · Cited by 3
Georgianos, P. I., Kourtidou, C., Leivaditis, K., Κόλλιας, Α., & Liakopoulos, V. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2468954 · Cited by 2
“…m 2 or urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g participating in the NHANES (National Health and Nutrition Examination Survey) [10], the rates of ACEI/ARB use progressively rose from 1999 to 2014, but for uncertain reasons, this rising trend appeared to reach a plateau after…”
Mayhand, K. N., Alicic, R. Z., Kornowske, L. M., Jones, C. R., Daratha, K. B., Reynolds, C., Nicholas, S. B., Thorpe, R. J., Bui, A. A. T., Norris, K. C., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04263-4 · Cited by 3
Pecoits‐Filho, R., Kanda, E., Kashihara, N., Ofori‐Asenso, R., Chen, H., Pentakota, S., Järbrink, K., Sánchez, J. J. G., Lam, C. S. P., Fishbane, S. N., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf175 · Cited by 3
AlSahow, A., Alyousef, A., AlSabti, N., Alhelal, B. A., AlRajab, H., Alqallaf, A. K. E. A., Bahbahani, Y., Alkandari, A., Mazroue, A., dewidar, N., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03794-6 · Cited by 2
“This could not be explained by hyperkalemia, since mean potassium level was normal for all subgroups, and this unfortunately is a widespread finding [17].”
BackgroundChang, T. I., Cluett, J., Cohen, D. L., Drawz, P. E., Hudson, J. Q., Kramer, H., Rahman, M., & Awdishu, L. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.07.006 · Cited by 1
Self-citationNew Perspectives in COPD Management
Yawn (2021) · The Journal of Family Practice · doi:10.12788/jfp.0220 · Cited by 2
Ivanova, G. T., Khasun, M. H., Parastaeva, M., Rumyantsev, A. S., & Николаевна, Б. О. (2024) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2024-2424 · Cited by 1
Santana, R., Umana, C. D., Oo, Z. T., Kolli, S. T., Bejugam, V. R., Piplani, S., ALJAREH, A. W., Garcia, B. T., Raptis, D., ASUZU, C., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.08.029 · Cited by 1
Decision Points in the Management of Patients with Diabetic Kidney Disease
Weir (2021) · The Journal of Family Practice · doi:10.12788/jfp.0217 · Cited by 1
Utilizing CGM Ambulatory Glucose Profiles to Optimize Diabetes Management
Miller (2021) · The Journal of Family Practice · doi:10.12788/jfp.0226 · Cited by 2
Neuen, B. L., Jun, M., Wick, J., Kotwal, S. S., Badve, S. V., Jardine, M., Gallagher, M., Chalmers, J. P., Nallaiah, K., Perkovic, V., et al. (2023) · medRxiv · doi:10.1101/2023.06.26.23291881 · Cited by 1
Diabetic Kidney Disease: It Don’t Get No Respect
Brunton, S. (2020) · Clinical Diabetes · doi:10.2337/cd20-0003
Pharmacoepidemiology in Cardiorenal Medicine
Tecson, K. M., & Shafiei, S. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_24
Inoue, K., DeJong, C., & Nangaku, M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.12.008
Rossignol, P., & Agarwal, R. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab061
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225 · Cited by 3
“This is a concern since patients with early-stage CKD may not be receiving appropriate treatments or, worse yet, may be receiving potentially nephrotoxic medications, leading to more rapid rates of disease progression.(5,10) Diabetes and hypertension are the 2 principal causes of CKD and ESKD,(5) accounting for 47% an…”
BackgroundImproving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Morton, J. I., McDonald, S. P., Salim, A., Liew, D., Shaw, J. E., & Magliano, D. J. (2021) · doi:10.2337/figshare.14363783.v1
Goraya, N., & Moran, J. D. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00032022
Shubrook, J. H., Neumiller, J. J., Alicic, R. Z., Manley, T., & Tuttle, K. R. (2023) · Diabetology · doi:10.3390/diabetology4040039
“A recent report advised that the daily rinsing of the genital area after voiding and before bedtime significantly lessened the risk of genital mycotic infections (6/125 versus 51/125, p = 0.015) and also increased adherence to SGLT-2 inhibitor treatment over a three-year period [55].”
BackgroundInfluentialLeite, M. M., & Flores, A. M. N. (2024) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e16351.2024
Metadata
- Authors
- Murphy, D. P., Drawz, P. E., & Foley, R. N.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Foley, Robert N.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2019-06-05
- Volume
- 30
- Issue
- 7
- Pages
- 1314-1321
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC6622408
- OpenAlex
- W2948831315
- Cited by
- 106
- References
- 45
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 11 · 2023: 21 · 2022: 13 · 2021: 32 · 2020: 10 · 2019: 4
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- ACE inhibitors, angiotensin receptor blockers, chronic kidney disease, antihypertensive therapy, racial and ethnic disparities, diabetes mellitus, cardiovascular disease, NHANES, community-based care, albuminuria, estimated glomerular filtration rate, Hispanic health disparities
- MeSH terms
- Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Female, Glomerular Filtration Rate, Humans, Hypertension, Male, Middle Aged, Renal Insufficiency, Chronic, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.